CytoLynx, a joint venture created by Cytovia and TF Capital and supported by other leading investors, is a China-based R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline. It aims to bring disruptive medicines to Greater China and world-wide.
CytoLynx is building infrastructure that will allow for global development and commercialization of new products originated in its Shanghai R&D Center.
CytoLynx will also serve as a development and commercialization platform for additional Cytovia products, as well as in-licensed immuno-oncology assets.
CytoLynx will be led by CEO Laura Hong, MD, PhD.